Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;20(2):351-355.
doi: 10.1111/jch.13169. Epub 2018 Jan 16.

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension

Steven G Chrysant  1
Affiliations

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension

Steven G Chrysant. J Clin Hypertens (Greenwich). 2018 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest and that no funds were received for the preparation of this article.

References

    1. Ruilope LM, Dukat A, Bohm M, et al. Blood pressure reduction with LCZ696, a novel dual‐acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double‐blind, placebo‐controlled, active comparator study. Lancet. 2010;375:1255‐1266. - PubMed
    1. Solomon SD, Claggett B, McMurray JJ, et al. Combined, neprilysin and renin‐angiotensin system inhibition in heart failure with reduced ejection fraction: a meta‐analysis. Eur J Heart Fail. 2016;18:1238‐1243. - PubMed
    1. Chrysant SG. LCZ696, angiotensin AT1 receptor blocker/neprisylin inhibitor for the treatment of heart failure and hypertension. Drugs of the Future. 2011;36:183‐190.
    1. Chrysant SG, Chrysant GS. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich). 2004;6:445‐451. - PubMed
    1. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic implications. Heart Fail Rev. 2007;12:131‐142. - PubMed

LinkOut - more resources